Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Agent, Into Achondroplasia
In preclinical models, TYRA-300 demonstrated significant increases in growth and bone lengthPhase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024-Conference call and webcast today, March 1st, at 8:00…